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Background: Frequent feeds with carbohydrate-rich meals or continuous enteral feeding has been the therapy of
choice in glycogen storage disease (Glycogenosis) type III. Recent guidelines on diagnosis and management
recommend frequent feedings with high complex carbohydrates or cornstarch avoiding fasting in children, while
in adults a low-carb-high-protein-diet is recommended. While this regimen can prevent hypoglycaemia in children it
does not improve skeletal and heart muscle function, which are compromised in patients with glycogenosis IIIa.
Administration of carbohydrates may elicit reactive hyperinsulinism, resulting in suppression of lipolysis, ketogenesis,
gluconeogenesis, and activation of glycogen synthesis. Thus, heart and skeletal muscle are depleted of energy
substrates. Modified Atkins diet leads to increased blood levels of ketone bodies and fatty acids. We hypothesize
that this health care intervention improves the energetic balance of muscles.
Methods: We treated 2 boys with glycogenosis IIIa aged 9 and 11 years with a modified Atkins diet (10 g carbohydrate
per day, protein and fatty acids ad libitum) over a period of 32 and 26 months, respectively.
Results: In both patients, creatine kinase levels in blood dropped in response to Atkins diet. When diet was withdrawn
in one of the patients he complained of chest pain, reduced physical strength and creatine kinase levels rapidly
increased. This was reversed when Atkins diet was reintroduced. One patient suffered from severe cardiomyopathy
which significantly improved under diet.
Patients with glycogenosis IIIa benefit from an improved energetic state of heart and skeletal muscle by introduction of
Atkins diet both on a biochemical and clinical level. Apart from transient hypoglycaemia no serious adverse effects were
observed.
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Glycogen storage disease type III (GSD III) is an inherited
metabolic disease caused by deficiency of the glycogen
debranching enzyme amylo-1,6-glucosidase and results in
the accumulation of abnormal glycogen (‘limit dextrin’).
Two clinical types of GSD III are known:
GSD IIIa with liver and muscle involvement and GSD
IIIb only with liver involvement [1,2].
In GSD IIIa, cardiomyopathy may lead to considerable
morbidity [3-5].
Hypoglycaemia can be prevented by frequent feeding
of carbohydrate–rich meals, continuous enteral feeding
or administration of uncooked cornstarch [6-8]. This* Correspondence: das.anibh@mh-hannover.de
1Clinic for Paediatric Kidney-, Liver and Metabolic Diseases,
Carl-Neuberg-Str.1, D-30625 Hannover, Germany
Full list of author information is available at the end of the article
© 2014 Mayorandan et al.; licensee BioMed Ce
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.regimen does not improve cardiac and skeletal muscle
function [9]. Cardiac dysfunction is treated symptomat-
ically. Recent studies have advocated a protein-rich diet
[10-12] which has also been supplemented with ketone
bodies [9]. Even enzyme replacement therapy in GSD III
has been suggested underpinning the unmet need for an
effective treatment [13]. Krishnani et al. published
guidelines on diagnosis and management of GSD III
advocating the prevention of fasting, frequent feeds
with high complex carbohydrates or administration of
cornstarch in children whereas adults may be treated by
a low-carb-high-protein-diet [14].
While a carbohydrate-rich diet prevents fasting
hypoglycaemia in most cases it may lead to energy
depletion of skeletal and heart muscle by the following
mechanism: The administration of high-carbohydrate
food induces reactive hyperinsulinism with subsequentntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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and activation of glycogen synthesis [15]. Thus, fatty
acids, ketone bodies and glucose as fuel for skeletal
muscle and heart are depleted.
Suppression of insulin secretion seems desirable in
GSD IIIa, however simple hypocaloric catabolism will
result in hypoglycaemia. The eucaloric ketogenic diet
results in increased blood levels of ketone bodies as
alternative substrates for the brain. At the same time,
elevated levels of ketone bodies and fatty acids serve as
energy substrates for heart [16] and skeletal muscle.
Thus, the energetic balance of muscles is improved.
Compliance with the classical ketogenic diet is often
hampered by unpalatability and the necessity of calculat-
ing the ratio of fat to protein and carbohydrate intake
which is supposed to be 4 (3):1. To improve compliance,
we suggest using a modified Atkins diet (MAD) where
daily carbohydrate intake is limited to 10 g while free
access to protein is allowed and fat intake is encouraged.
We report treatment of 2 boys with GSD IIIa by MAD.
Methods
Patient 1
The boy of Sri Lankan extraction was 9 years old at the
initiation of MAD. He was diagnosed with GSD III at
the age of 7 months due to motor retardation, myop-
athy, and hepatomegaly.
Initially, he presented with elevated liver enzymes
(ALT 711 U/l, AST 733 U/l and y-GT 52 U/l) and an in-
creased creatine kinase activity (CK) in serum (514 U/l).
The patient suffered repeated episodes of hypoglycaemia
with minimal blood glucose levels of 0.1 mmol/l. GSD
III was suspected and confirmed by the absence of
amyloglucosidase activity in blood cells. Elevated glycogen
concentration in red blood cells of 20 mg/dl (normal
range 0–10 mg/dl) was in line with this diagnosis.
Mutation analysis showed homozygosity for the mutation
c.4256dupC. Echocardiography revealed slight hyper-
trophic cardiomyopathy.
The patient was initially treated with intravenous
glucose infusion subsequently maltodextrin was given
by continuous enteral feeding at night to prevent
hypoglycaemia at a rate of 7–9 mg/kg per min. Stabilization
of blood glucose was finally achieved by dietary treatment
with uncooked cornstarch, which cannot be used before
the age of 6–8 months due to immaturity of digestive
enzymes. In the following years, feeding of carbohydrate
and protein-rich meals as well as uncooked cornstarch
over night was continued.
This classical diet stabilized plasma glucose levels,
but echocardiographic follow-up showed progression
of left ventricular and septal hypertrophy as well as left
ventricular outflow tract obstruction (LVTO) under
medication with verapamil. Interventricular septal wallthickness increased to 1.4 cm and LVOT-gradient rose
to 20 mm Hg. ECG (electrocardiography) revealed
signs for biventricular hypertophy and abnormal repo-
larisation with elevation of ST-segments (0.5 mV). The
boy showed compromised physical capacity with initial
difficulties in climbing stairs. Sport activities at school
were very limited; he could hardly walk a distance of
100 metres without interruption. Constantly elevated
levels of CK in serum (up to 5,300 U/l) over several
years indicated significant muscle involvement.
As cardiomyopathy rapidly progressed we tried a
protein-rich diet with a daily protein allowance of 3 g/kg
(19% of total energy intake). However, cardiomyopathy
continued to progress.
Patient 2
The second patient was a boy of Iranian origin who was
11 years old at the start of MAD. In early childhood,
recurrent episodes of hypoglycaemia occurred. The boy
showed retardation in growth and motor development.
At the age of 10 years, he was referred to our hospital
with severe muscle involvement. No sport activities were
possible and the boy had even difficulties climbing stairs
due to muscle weakness. Moreover, he complained of
chest pain after physical exercise and recurrent nausea.
The glycogen concentration in red blood cells was
elevated (23 mg/dl, normal range: 0–10 mg/dl), absence
of amyloglucosidase activity in red blood cells confirmed
the diagnosis of GSD III. The boy was homozygous for
the mutation c.753_756del. Initial cardiac investigations
revealed minor concentric hypertrophic cardiomyopathy
with a prolonged QTc-time.
Modified Atkins diet
The patients were hospitalized for the initiation of the
modified Atkins diet for 7–14 days. This allowed close
monitoring of both patients and comprehensive dietary
training of the patients and their families. MAD con-
sisted of meals low in carbohydrate with a total of 10 g
carbohydrates per day. Families were given exchange
tables for rough estimation of nutrient intake and special
low-carbohydrate food was suggested. Patients were
encouraged to eat food rich in fat and protein like meat,
fish, eggs, nuts ad libitum. Vitamins and minerals were
supplemented according to dietary recommendations.
Compared to the classical ketogenic diet MAD is easier
to implement in daily life as fat and protein intake do
not have to be calculated which facilitates compliance.
In ketogenic diet a 4:1 or 3:1 ratio of fat versus protein
and carbohydrate has to be followed which involves
calculating fat, protein and carbohydrate intake. While
commercially available ketogenic formula feeds can
facilitate daily life for infants during the first few months
of life compliance is more difficult in the older child.
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the first weeks after introduction of MAD thus uncooked
cornstarch had to be continued. In patient 1 uncooked
cornstarch at night could be slowly reduced over a period
of 5 months and was then discontinued, patient 2 received
uncooked cornstarch for two months only.
Both patients were followed in our outpatient clinics
(patient 1: 32 months, patient 2: 26 months after start of
MAD) and were seen every 3–6 months.
To assess the metabolic status and therapy compliance
the following parameters were recorded every 3 to
6 months: ketone bodies in plasma and urine, CK-levels
in serum, liver function, acylcarnitine profile, amino
acids in plasma, lipids and glucose in serum. Cardiac
investigations via echocardiography and electrocardiog-
raphy were performed every 3–6 months. At home, par-
ents monitored ketone bodies in urine via dip stick
testing.
While the family of patient 1 had no problems sticking
to MAD, the family of patient 2 decided to stop MAD
after 3 months and switched to traditional cooking.
Patient 2 and his family were noncompliant due to
language difficulties and lack of comprehension of the
disease. There were many (psycho-) social problems as
the family had refugee status. In the following months
we were able to convince the family to resume MAD.
Results
Dietary treatment with MAD was well tolerated apart
from transient hypoglycaemia. In patient 1 carbohydrate
intake dropped from 10 g/kg per day to 0.4 g/kg per day
under MAD, protein intake increased from 3 g/kg per day
to 7 g/kg per day while fat intake increased from 1.6 g/kg
per day to 8 g/kg per day. In patient 2 carbohydrate intakeTable 1 Laboratory parameters and echocardiographic studie
Time
Parameter −6 m −3 m 0 m +4 m
Metabolic monitoring
KB [mM] - - - 5.6
CK [U/l] (<170) 2646 3400 2650 1735
Lipids
LDL-C [mg/dl] (<130) 126 120 111 120
TG [mg/dl] (<140) 180 184 180 183
Cardiac monitoring
ProBNP [ng/l] (<84) 555 - 603 -
LVOT-gradient [mm Hg] 20 18 20 20
PWT [cm] 0.8 0.8 0.8 0.8
VST [cm] 1.4 1.3 1.4 1.4
Start of MAD at 0 months (0 m).
Laboratory parameters in blood: KB: Ketone Bodies in plasma; LDL-C: LDL-cholestero
natriuretic peptide in serum;
Echocardiography: LVOT-gradient: Left Ventricular Outflow Tract-gradient; PWT: Posunder MAD was 0.5 g/kg per day, fat intake 6 g/kg per
day and protein intake 5 g/kg per day. No dietary assess-
ment was done in this patient prior to MAD introduction.
In both patients dietary recommendations according to
DACH (German-Austrian-Swiss association for nutrition)
were met as judged by dietary protocols during MAD.
Patient 1
Essential laboratory and echocardiographic parameters
are summarized in Table 1. Plasma concentrations of
ketone bodies ranged from 1.7 to 7.8 mmol/l. The CK
activity in blood fell significantly under MAD. Cardiac
function improved as judged by echocardiography and
ECG. Left ventricular outflow tract (LVOT) obstruction
significantly improved; the gradient decreased from
20 mm Hg before initiation of MAD to 5 mm Hg after
32 months of MAD, ventricular septum thickness was
reduced from 1.4 cm to 0.8 cm in the same period while
posterior wall thickness remained constant (Table 1).
This improvement is reflected in NT-Pro BNP (N-
terminal fragment pro brain natriuretic peptide)-levels
which were very high and normalized under MAD. Be-
fore MAD, the ECG revealed biventricular hypertrophy
and abnormalities in repolarisation with a ST-elevation
of 0.5 mV. After 32 months of MAD, repolarisation nor-
malized, ST-elevation disappeared, while signs for left
ventricular hypertrophy were still observed.
The patient showed an increase of stamina and is able
to walk 500 metres without interruption. Weight gain
and growth are commensurate with age.
Apart from transient asymptomatic hypoglycaemia no
side effects were observed. LDL-cholesterol levels were
in the reference range, triglycerides were slightly in-
creased (Table 1).s in patient 1
+8 m +12 m +18 m +24 m +32 m
7.8 5.9 4.5 3.0 2.7
670 602 621 668 599
115 125 140 118 130
192 180 224 181 250
- - - - 72
13 8 9 7 5
0.7 0.7 0.7 0.8 0.7
1.1 1.2 1.0 1.0 0.8
l in serum; TG: Triglycerides in serum; ProBNP: N-terminal fragment pro brain
terior Wall Thickness; VST: Ventricular Septum Thickness.
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MAD resulted in elevated ketone bodies in plasma with
a maximum of 7.8 μmol/l. A decrease of the CK-level
from 3,895 to 2,846 U/l was detected over a period of two
months. Chest pain after physical exercise and nausea
disappeared. The boy gained more stamina. Subsequently,
under dietary noncompliance and complete withdrawal of
MAD, ketosis was lost. CK-levels increased to 5,192 U/l.
Chest pain after physical exercise reappeared and a
reduction of physical capacity was observed. No cardiac
follow-up could be performed due to incompliance.
When MAD was resumed ketosis was quickly re-
established, CK-levels fell from 5,192 U/l to 3,000 U/l
within 4 weeks (Figure 1). Chest pain and muscular
weakness disappeared.
Hypertrophic cardiomyopathy disappeared, ECG
normalized.
No serious side-effects resulting from MAD were
observed, LDL-cholesterol and triglyceride levels remained
normal (results not shown). Weight gain and growth were
appropriate for age.
Discussion
GSD III has classically been treated with frequent
carbohydrate-rich meals. While this therapeutic option
prevents hypoglycaemia it does not improve muscle [17]
and cardiac dysfunction [18,19] including arrythmias [20].
We hypothesized that reactive hyperinsulinism result-
ing from high carbohydrate feeding is responsible for
the depletion of energy substrates (fatty acids and ketone
bodies) in skeletal and cardiac muscles followed by
muscle dysfunction. Furthermore, elevated levels ofFigure 1 CK- and ketone body levels in patient 2.insulin activate glycogen synthase and promote glycogen
storage in myocytes [15]. This may exacerbate subtle
energy deficiency which has been discussed to play a
pathophysiological role in glycogenoses [21,22].
Our therapeutic approach using MAD led to clinical
improvement/stabilisation of skeletal muscle and cardiac
manifestations in both our patients. CK-levels in plasma
as an objective quantitative parameter for muscle dys-
function dropped under MAD. Quantitative tests of
muscle strength were not performed. A (involuntary)
cross-over study took place in patient 2.
Heart function improved as judged by echocardiog-
raphy and ECG in patient 1. Pro BNP as a marker
for compromised heart function impressively improved
under MAD. Detailed studies of heart function were
not performed in patient 2 as heart function was not
severely compromised before MAD was initiated.
Most likely, the underlying pathophysiological mech-
anism is prevention of hyperinsulinism and its conse-
quences. Daily carbohydrate allowance was low in both
patients at 0.4-0.5 g/kg which is sufficient to suppress
insulin secretion. Adequate supply of energy substrates
under MAD has a positive effect on muscle function.
Furthermore, ketosis is known to activate mitochondrial
succinate dehydrogenase in heart thus improving the
energetic balance [23]. Reduction of the glycogen synthase
activity with consecutive reduction of stored glycogen
may be another beneficial factor. We observed transient
hypoglycaemia at the start of MAD when ketone bodies
were not yet elevated. Potential side effects of MAD as
gastrointestinal symptoms, fatigue and dyslipidaemia [24]
were not observed in our patients. So far, it is not clear
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trations to secure adequate energy supply for heart and
skeletal muscles.
It is not clear why the response to MAD in patient 2
was less pronounced as judged by CK-levels. Response
may depend on the specific mutation underlying GSD
IIIa, alternatively dietary compliance may have been
incomplete between visits in our outpatient clinics.
A similar stabilization and reversal of GSD IIIa-related
cardiomyopathy and myopathy of respiratory muscles
has been reported in patients on a high-protein diet
[10-12] which is also suggested in a recent guideline
[14]. We speculate that the underlying mechanism of
this observation may be the prevention of reactive
hyperinsulinism as well. Valayannopoulos et al. reported
a case with improvement of cardiomyopathy under high-
protein diet combined with administration of D, L-3-
Hydroxybutyrate. The supply of exogeneous ketone bodies
is unphysiological and requires compliance of the patient.
Sticking to a ketogenic diet is more demanding than
following MAD. Thus, MAD may be more efficient and
comfortable for the daily routine of the patient.
Conclusion
In summary, we report 2 boys with GSD IIIa who bene-
fited from MAD. CK-levels fell, cardiac function improved
and exercise tolerance increased. Apart from transient
asymptomatic hypoglycaemia at the initiation of MAD no
serious adverse effects were observed.
Consent
Written informed consent was obtained from the parents
of patient 1 and the mother of patient 2 for the publication
of this report.
Abbreviation
CK: Creatine kinase; CK-MB: Creatine kinase - MB; GSD III: Glycogen storage
disease type III; LVOT: Left ventricular outflow tract; MAD: Modified Atkins
diet; Pro BNP: N-terminal fragment pro brain natriuretic peptide.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SM collected patients’ data and drafted the manuscript. UM carried out
dietary consultation and monitored MAD, she contributed to the manuscript
with her expertise. HH contributed to the manuscript with his expertise.
AMD designed and coordinated the study, he finalized the manuscript.
All authors read and approved the final version of the manuscript.
Acknowledgements
We are grateful to both patients and their families for participating in this
study. We thank Vitaflo GmbH, Germany for financial support.
Author details
1Clinic for Paediatric Kidney-, Liver and Metabolic Diseases,
Carl-Neuberg-Str.1, D-30625 Hannover, Germany. 2Present address:
Department of Paediatrics, University Hospital Münster,
Albert-Schweitzer-Campus 1, D-48161 Münster, Germany.Received: 31 July 2014 Accepted: 14 November 2014References
1. Das AM, Steuerwald U, Illsinger S (2010): Inborn Errors of Energy
Metabolism Associated with Myopathies. J Biomed Biotechnol 2010.
http://dx.doi.org/10.1155/2010/340849.
2. Dimauro S, Hartwig GB, Hays A, Eastwood AB, Franco R, Olarte M, Chang M,
Roses AD, Fetell M, Schoenfeldt RS, Stern LZ: Debrancher deficiency:
neuromuscular disorder in 5 adults. Ann Neurol 1979, 5(5):422–436.
3. Miller CG, Alleyne GA, Brooks SE: Gross cardiac involvement in glycogen
storage disease type III. Br Heart J 1972, 34(8):862–864.
4. Olson LJ, Reeder GS, Noller KL, Edwards WD, Howell RR, Michels VV: Cardiac
involvement in glycogen storage disease III: morphologic and
biochemical characterization with endomyocardial biopsy. Am J Cardiol
1984, 53(7):980–981.
5. Akazawa H, Kuroda T, Kim S, Mito H, Kojo T, Shimada K: Specific heart
muscle disease associated with glycogen storage disease type III: clinical
similarity to the dilated phase of hypertrophic cardiomyopathy. Eur Heart
J 1997, 18(3):532–533.
6. Gremse DA, Bucuvalas JC, Balistrerie WF: Efficacy of cornstarch therapy in
type III glycogen-storage disease. Am J Clin Nutr 1990, 52(4):671–674.
7. Fernandes J, Leonard JV, Moses SW, Odièvre M, di Rocco M, Schaub J,
Smit GP, Ullrich K, Durand P: Glycogen storage disease: recommendations
for treatment. Eur J Pediatr 1988, 147(3):226–228.
8. Wolfsdorf JI, Weinstein DA: Glycogen storage diseases. Rev Endocr Metab
Disord 2003, 4(1):95–102.
9. Valayannopoulos V, Bajolle F, Arnoux JB, Dubois S, Sannier N, Baussan C,
Petit F, Labrune P, Rabier D, Ottolenghi C, Vassault A, Broissand C, Bonnet D,
De Lonlay P: Successful treatment of severe cardiomyopathy in glycogen
storage disease type III with D, L -3-hydroxybutyrate, ketogenic and
high-protein diet. Pediatr Res 2011, 70(6):638–641.
10. Sentner CP, Caliskan K, Vletter WB, Smit GPA: Heart failure due to severe
hypertrophic cardiomyopathy reversed by low calorie, high protein
dietary adjustments in a glycogen storage disease type IIIa patient.
JIMD Rep 2012, 5:13–16.
11. Dagli AI, Zori RT, McCune H, Ivsic T, Maisenbacher MK, Weinstein DA:
Reversal of glycogen storage disease type IIIa –related cardiomyopathy
with modification of diet. J Inherit Metab Dis 2009, 32(Suppl 1):103–106.
12. Kiechl S, Willeit J, Vogel W, Kohlendorfer U, Poewe W: Reversible of severe
myopathy of respiratory muscles due to adult-onset type III glycogenosis.
Neuromuscul Disord 1999, 9(6–7):408–410.
13. Sun B, Fredrickson K, Austin S, Tolun AA, Thurberg BL, Kraus WE, Bali D,
Chen YT, Kishnani PS: Alglucosidase alfa enzyme replacement therapy as
a therapeutic approach for glycogen storage disease type III. Mol Genet
Metab 2013, 108(2):145–147.
14. Kishnani PS, Austin SL, Arn P, Bali DS, Boney A, Case LE, Chung WK, Desau DM,
El-Gharbawy A, Haller R, Smit GPA, Smith AD, Hobson-Webb LD, Wechsler SB,
Weinstein DA, Watson MS: Glygogen storage disease type III: diagnosis and
management guidelines. Genet Med 2010, 12(7):446–463.
15. Vestergaard H: Studies of gene expression and activity of hexokinase,
phosphofructokinase and glycogen synthase in human skeletal muscle
in states of altered insulin- stimulated glucose metabolism. Dan Med Bull
1999, 46(1):13–34.
16. Neely JR, Rovetto MJ, Oram JF: Myocardial utilization of carbohydrate and
lipids. Prog Cardiovasc Dis 1972, 15(3):289–329.
17. Slonim AE, Coleman RA, Moses WS: Myopathy and growth failure in
debrancher enzyme deficiency: improvement with high-protein nocturnal
enteral therapy. J Pediatr 1984, 105(6):906–911.
18. Austin SL, Proia AD, Spencer-Manzon MJ, Butany J, Wechsler SB, Krishnani
PS: Cardiac pathology in glycogen storage disease type III. JIMD Rep 2012,
6:65–72.
19. Smit GPA, Fernandes J, Leonard JV, Matthews EE, Moses SW, Odievre M,
Ullrich K: The long-term outcome of patients with glycogen storage
diseases. J Inherit Metab Dis 1990, 13(4):411–418.
20. Tada H, Kurita T, Ohe T, Shimomura K, Ishihara T, Yamada Y, Osawa N:
Glycogen storage disease type III associated with ventricular tachycardia.
Am Heart J 1995, 130(4):911–912.
21. Preisler N, Pradel A, Husu E, Madsen KL, Becquemin MH, Mollet A,
Labrune P, Petit F, Hogrel JY, Jardel C, Maillot F, Vissing J, Laforet P: Exercise
Mayorandan et al. Orphanet Journal of Rare Diseases  (2014) 9:196 Page 6 of 6intolerance in glycogen storage disease type III: weakness or energy
deficiency? Mol Genet Metab 2013, 109(1):14–20.
22. Vissing J, Haller JG: Mechanisms of exertional fatigue in muscle
glycogenoses. Neuromuscul Disord 2012, 22(Suppl 3):168–171.
23. Balietti M, Fattoretti P, Giorgetti B, Casoli T, Di Stefano G, Solazzi M,
Platano D, Aicardi G, Bertoni- Freddari C: A ketogenic diet increases
succinic dehydrogenase activity in aging cardiomyocytes. Ann N Y Acad
Sci 2009, 1171:377–384.
24. Auvin S: Should we routinely use modified Atkins diet instead of regular
ketogenic diet to treat children with epilepsy? Seizure 2012, 21:237–240.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
